Evotec shares drop on guidance cut, 'ugly' Q2
14/07/2026 07:02
BUZZ-Evotec shares drop on guidance cut, 'ugly' Q2 ** Shares in Evotec EVTG.DE plummet about 20% in early Frankfurt trade after it cut 2026 outlook following what a local trader describes as "ugly" Q2 preliminaries
** The German drug discovery firm now expects 2026 revenue of €570-610 million ($649-695 million) vs €700-780 million previously; it cites delays into 2027 to large strategic partnerships
** RBC says Q2 represents a clear deterioration, citing revenue 16% below consensus
** "Despite management's confidence that the existing strategic programmes and the pipeline are delayed, not lost, we think it will have a tough time convincing the market as such," RBC says
** Full financial results for Q2 and H1 to be published on August 13
($1 = 0.8777 euros)
(Reporting by Anastasiia Kozlova)
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases